Every 8-K that Beyond Air, Inc. (XAIR) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow XAIR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full XAIR filings page.
Beyond Air, Inc. entered into an employment agreement with Chief Executive Officer Robert Goodman, effective September 23, 2026; he will continue reporting to the Board. The agreement has no fixed term and sets annual base salary at not less than $650,000, a 60% target annual bonus and a potential payout of 0% to 150% of target based on management objectives.
For termination without Cause (other than death or Disability) or resignation for Good Reason, terms provide accrued base salary, benefits and earned unpaid bonus, 12 months of salary continuation and COBRA premium reimbursement for 12 months, subject to timely election. If termination occurs from three months before through 12 months after a Change in Control, salary is paid in a lump sum equal to 24 months of base salary and COBRA reimbursement extends to 18 months. CFO Daniel Moorhead’s annual base salary increased from $325,000 to $463,000, effective September 23, 2026.
Beyond Air, Inc. (XAIR) reported results for the quarter ended June 30, 2026 and provided a corporate update. Revenue was $1.8 million, roughly flat year over year, while gross margin improved to 13% from 9%. Net loss attributable to common stockholders was $7.9 million, or $11.00 per share, compared with a loss of $7.7 million, or $30.67 per share, a year earlier.
As of June 30, 2026, cash, cash equivalents, restricted cash and marketable securities totaled $15.2 million, against $22.2 million of long-term debt and total liabilities of $30.1 million, leaving stockholders’ equity at $2.8 million. After quarter-end, the company completed an up to $30.1 million financing, including $10.2 million in upfront gross proceeds and up to an additional $20.0 million from potential warrant exercises. Management reaffirmed revenue guidance of $8 million for calendar 2026 and $16–$18 million for 2027, and highlighted ongoing FDA review of a PMA supplement for its second-generation LungFit PH system, with approval expected in the second half of 2026.
Beyond Air, Inc. reports that it has regained compliance with Nasdaq’s minimum bid price requirement after implementing a 1-for-20 reverse stock split of its common stock on July 13, 2026.
Nasdaq confirmed compliance in an August 6, 2026 letter, based on the company’s common stock maintaining a closing bid of at least $1.00 per share for 17 consecutive trading days from July 13 through August 4, 2026. This also satisfies conditions previously set by a Nasdaq Hearings Panel for continued listing on The Nasdaq Capital Market.
The Panel imposed a Discretionary Panel Monitor for one year from the compliance letter. During this monitor period, any failure to meet a Nasdaq continued listing requirement will result in an immediate delisting determination, without the opportunity to submit a compliance plan or obtain additional time from Nasdaq staff; any appeal would go directly to the Hearings Panel.
Beyond Air, Inc. entered into a private placement with institutional investors and insiders to raise approximately $10.2 million in upfront gross proceeds. The company will issue 167,011 common shares and pre-funded warrants for up to 1,638,835 shares, each paired with Series A and Series B common stock warrants.
The warrants cover up to 1,805,846 shares each for Series A and Series B at a $5.51 exercise price, contributing to potential aggregate proceeds of up to $30.1 million if fully exercised for cash. Pre-funded warrants are exercisable at $0.0001, subject to 19.99% ownership caps; other warrants have 9.99% caps, with expirations tied to FDA action on LungFit PH II or five years after issuance. Net proceeds are intended for working capital and general corporate purposes, and the company agreed to resale registration and temporary limitations on new equity issuances.
Beyond Air, Inc. approved and is implementing a 1-for-20 reverse stock split of its common stock. The change becomes effective at 12:01 a.m. Eastern Time on July 13, 2026, when shares begin trading on a split-adjusted basis on Nasdaq under the existing symbol XAIR.
The company is using this reverse split to raise its per-share bid price above $1.00 to regain compliance with Nasdaq Listing Rule 5550(a)(2), which requires trading at or above $1.00 for at least 10 consecutive trading days. Each stockholder’s total shares will be divided by 20 and rounded up to the nearest whole share, so no fractional shares or cash payments will result.
The company remains authorized to issue 500,000,000 shares of common stock and 10,000,000 shares of preferred stock, and the par value of both classes is unchanged. Management states that stockholders’ percentage ownership and voting power should remain essentially the same, aside from minor adjustments from rounding.
Beyond Air, Inc. reported strong growth for its fiscal year ended March 31, 2026 and announced a change in fiscal year-end to December 31. Full-year revenue rose 107% to $7.7 million, while net loss narrowed to $33.2 million, or $4.01 per share, from $46.6 million.
For the March quarter, revenue increased 66% to $1.9 million and gross margin turned positive, but the company still recorded a quarterly net loss of $10.3 million. Operating expenses fell sharply year-over-year as research and development and general and administrative costs declined.
Beyond Air ended March 31, 2026 with $17.3 million in cash, cash equivalents, restricted cash and marketable securities and $21.6 million of total long-term debt. The company issued revenue guidance of $8 million for calendar 2026 and $16–$18 million for 2027, assuming commercial launch of its second-generation LungFit PH system.
Beyond Air, Inc. stockholders approved giving the board discretion to implement a reverse stock split within a range of 1-for-2 to 1-for-20, with no change to authorized share counts. At the June 18, 2026 special meeting, 5,177,506 votes were cast in favor, 1,222,793 against and 87,461 abstained, from 12,692,684 shares outstanding as of the April 20, 2026 record date.
Immediately after the vote, the board approved a specific 1-for-20 reverse split ratio, combining every 20 outstanding shares of common stock into one share, to be effected after a certificate of amendment becomes effective. The company states it intends to use the split to increase its share price above $1.00 for at least ten trading days to regain compliance with Nasdaq Listing Rule 5550(a)(2) by July 31, 2026, while cautioning there is no assurance the split will be implemented as planned or achieve the desired effects.
Beyond Air, Inc. received a decision from a Nasdaq Hearings Panel granting its request to continue listing on The Nasdaq Stock Market, provided it regains compliance with Nasdaq Listing Rule 5550(a)(2), the Bid Price Rule, by July 31, 2026. The company remains compliant with all other Nasdaq continued listing requirements.
Once Beyond Air regains bid price compliance, it will be subject to a one-year Discretionary Panel Monitor period. If it fails any Nasdaq listing standard during that year, Nasdaq staff will issue a delisting determination without allowing a new compliance plan. Shareholders are scheduled to vote on a reverse stock split proposal at a special meeting on June 18, 2026, which the company expects could help it meet the bid price requirement.
Beyond Air, Inc. has received written notice from Nasdaq that its common stock is not in compliance with the $1.00 bid price requirement under Nasdaq Listing Rule 5550(a)(2), which is required for continued listing.
The company has requested a hearing before the Nasdaq Hearings Panel, which has been scheduled for May 14, 2026. This timely request stays any suspension or delisting action until the Panel issues a written decision, so the stock is expected to remain listed on Nasdaq during the hearing process.
The company cautions that there is no assurance the Panel will grant continued listing or that it will regain compliance with Nasdaq’s continued listing standards, and it includes forward-looking statement disclaimers referencing risks described in its Form 10-K and other SEC filings.
Beyond Air, Inc. reported that it received a Nasdaq notice on April 7, 2026 stating its common stock no longer meets the minimum $1.00 per-share bid price required by Nasdaq Listing Rule 5550(a)(2). The deficiency was triggered because the stock’s closing bid price stayed below $1.00 for thirty consecutive business days from February 23, 2026 to April 6, 2026, which violates the Bid Price Rule.
Because the company previously effected a 1-for-20 reverse stock split on July 14, 2025, Nasdaq rules make it ineligible for the usual 180-day cure period. As a result, its securities are subject to delisting unless it requests a hearing with the Nasdaq Hearings Panel by April 14, 2026. Beyond Air plans to request this hearing, which would automatically stay any suspension or delisting while the Panel reviews the case. During this appeal process, the stock is expected to continue trading on Nasdaq.
The company says it will closely track its bid price and is considering options to regain compliance with Nasdaq’s listing standards, including potentially using another reverse stock split. However, it cautions there is no assurance the Panel will grant continued listing or that compliance can be regained and maintained, underscoring a meaningful risk around its Nasdaq listing status.
Beyond Air, Inc. announced a leadership transition in which longtime CEO and director Steven A. Lisi resigned from all positions, effective March 27, 2026, and Robert Goodman, previously Chief Commercial Officer and a director, was appointed CEO. The company states Mr. Lisi’s resignation is not due to any disagreement with its operations or policies.
Under a Separation and Release of Claims Agreement, after a seven-business-day revocation period, Beyond Air will provide Mr. Lisi $650,000 in separation pay over 12 months and pay his COBRA premiums for 12 months. All of his unvested stock options and restricted stock unit awards as of March 27, 2026, will fully vest and remain exercisable for 24 months. The company has not yet entered into a new employment agreement with Mr. Goodman and reports no material changes to his existing compensation at this time.
Beyond Air, Inc. reported fiscal third-quarter 2026 revenue of $2.2 million, up 105% from $1.1 million a year earlier, driven by growing adoption of its LungFit PH nitric oxide system in the U.S. and abroad. Gross profit improved to $0.3 million from a gross loss of $0.2 million.
Operating costs declined, with research and development down to $2.4 million and selling, general and administrative expenses reduced to $4.5 million. Net loss attributable to common stockholders narrowed to $7.3 million, or $0.85 per share, compared with a $13.0 million loss, or $2.96 per share, in the prior-year quarter.
The company ended the quarter with $17.8 million in cash, cash equivalents, restricted cash and marketable securities, plus $4.5 million of net proceeds from a subsequent private placement, and believes this supports a cash runway into calendar 2027. It maintained fiscal 2026 revenue guidance of $8–10 million and reported total long-term debt of $22.0 million.
Beyond Air highlighted commercial milestones, including its first LungFit PH sale to a VA Medical Center and international distribution now covering 40 countries. It also noted a binding agreement under which XTL Biopharmaceuticals will acquire 85% of NeuroNOS, with Beyond Air eligible for $1.0 million in cash, up to $31.5 million in milestones, and 19.9% equity in XTL.
Beyond Air, Inc. reported voting results from its 2026 Annual Meeting of Stockholders. Out of 8,009,488 shares outstanding as of December 3, 2025, a quorum of 4,221,408 shares, or 52.70%, was represented in person or by proxy.
Stockholders elected six directors to serve until the next annual meeting or until their successors are qualified. They also ratified WithumSmith+Brown, PC as independent registered public accounting firm for the fiscal year ending March 31, 2026.
In addition, stockholders approved the Eighth Amended and Restated 2013 Equity Incentive Plan, increasing shares reserved for issuance by 850,000, and approved the option to adjourn the meeting, although adjournment was not needed because all key proposals passed.
Beyond Air, Inc. entered into a private placement with an institutional investor, agreeing to sell 524,990 common shares at $1.272 per share, pre-funded warrants to purchase up to 3,405,828 shares at $1.2719 per warrant, and common warrants to purchase up to 3,930,818 shares, for aggregate gross proceeds of $5,000,000. The pre-funded warrants have a nominal exercise price of $0.0001 per share and the common warrants have an exercise price of $1.147 per share and expire on January 16, 2031. The company agreed to register the resale of the shares and warrant shares by filing a registration statement by February 4, 2026, with effectiveness targeted within 60 to 90 days after January 14, 2026, and may owe liquidated damages if these deadlines are missed. Beyond Air will pay Rodman & Renshaw LLC a cash fee of 7% of gross proceeds and reimburse up to $50,000 of expenses and is subject to specified restrictions on additional equity issuances and variable rate transactions for defined periods.
Beyond Air, Inc. reported that XTL Biopharmaceuticals Ltd. has signed a binding letter of intent to acquire Beyond Air’s 85% ownership interest in NeuroNOS Ltd., a biotechnology company developing disease‑modifying therapeutics for Autism Spectrum Disorder and neuro‑oncology. Under the proposed terms, Beyond Air would receive 19.9% of XTL’s issued share capital, $1 million in cash, and milestone-based contingent payments of up to $31.5 million.
The companies are working to finalize definitive agreements for the transaction, which are expected to be filed in a future current report or in Beyond Air’s Annual Report on Form 10‑K. The disclosure emphasizes that these statements are forward‑looking and may differ from actual results.
Beyond Air, Inc. appointed Denton "Duke" Dewrell as its principal financial officer and principal accounting officer on December 8, 2025.
Dewrell, age 39, has been the company’s Global Controller since April 2025, after serving as U.S. Controller from August 2024 and as Head of Finance and Controller of Beyond Cancer Ltd., a majority owned subsidiary, since August 2023.
He previously held senior finance roles at Updater Inc. and spent more than ten years in public accounting at Ernst & Young LLP. In his new role, he will continue to receive base compensation of $260,000 per year and participate in Beyond Air’s and Beyond Cancer’s equity incentive plans.
Beyond Air (XAIR) announced new financing and equity arrangements. The company entered an equity purchase agreement with Streeterville Capital for up to $20,000,000 in common stock, subject to a resale registration becoming effective and while no balance remains on a related note. The company agreed to file the registration statement by November 24, 2025. Share sales are bounded by a 4.99% Beneficial Ownership Limitation and Nasdaq’s 19.99% cap unless stockholder approval or pricing conditions under Rule 5635(d) are met.
Beyond Air also issued a secured promissory note with a principal amount of $12,050,000, receiving net proceeds of $12,000,000. The note matures in 24 months, carries 15% annual interest with no accrual for the first 12 months, and guarantees $1,800,000 of interest. Collateral includes a $6,000,000 cash DACA via a new subsidiary, with step-down mechanics as principal is repaid.
The company amended a prior loan to add a $2,000,000 term loan and issued five-year warrants to purchase 512,821 shares at $1.95, while repricing certain 2024 warrants to $1.95. Separately, 726,618 employee and director stock options were repriced to $1.95.
Beyond Air, Inc. filed an 8-K describing terms that limit the number of common shares issuable on exercise of certain warrants to prevent a holder from exceeding a stated "Beneficial Ownership Limitation." If an exercise would push the holder past that limit, the company will only issue the number of shares that keep the holder below the limit and will hold the remaining shares in abeyance until the holder notifies the company that issuance would comply with the limitation.
The filing lists exhibits including a Form of New Warrant, a Form of Inducement Letter, and a Press Release dated September 8, 2025. The filing also identifies Steven A. Lisi by name.
Beyond Air, Inc. filed a report describing that its subsidiary NeuroNOS Limited has been granted U.S. Food and Drug Administration Orphan Drug Designation for BA-101, its lead investigational therapy for treating glioblastoma. This status applies to serious rare diseases and can provide development incentives. The company released a press release with more details, furnished as an exhibit, and notes that this information is provided under Regulation FD and is not deemed filed for liability purposes or automatically incorporated into other securities law filings.
Beyond Air, Inc. filed a current report to note that it has issued a press release announcing its financial results for the first quarter ended June 30, 2025. The company stated that the press release, dated August 12, 2025, is attached as Exhibit 99.1 and is incorporated by reference into this report. The information in this report and the attached press release is being furnished rather than filed under securities laws, which affects how it is treated for certain liability and incorporation purposes.
Beyond Air held a Special Meeting of stockholders on June 20, 2025, where shareholders approved a significant Reverse Stock Split proposal. Out of 86,369,869 outstanding shares, 48,476,717 shares were represented at the meeting, constituting a quorum.
Key details of the approved proposal:
- Authorizes the Board to implement a reverse stock split within one year
- Split ratio range between 1-for-10 and 1-for-50
- Voting results: 41,924,612 votes in favor, 6,382,862 against, 169,243 abstentions
This strategic move gives the Board flexibility to consolidate shares, potentially improving the company's market position and stock price structure. The strong shareholder support (86.5% of votes cast in favor) demonstrates confidence in the Board's management strategy.
Beyond Air (NASDAQ: XAIR) reported several significant developments in this 8-K filing:
Key Events:
- Released financial results for fiscal quarter and year ended March 31, 2025 (detailed results not provided in filing)
- Appointed Robert Goodman to Board of Directors on June 16, 2025 - Qualified as independent director under Nasdaq standards - Notable experience with BioTelemetry, Philips Healthcare, Cardiocore, Thermo Fisher Scientific, and Pfizer
- Submitted PMA supplement application to FDA for LungFit PH II, their next-generation therapeutic nitric oxide generator
The company filed two press releases as exhibits (99.1 and 99.2) detailing the financial results and FDA submission respectively. The appointment of Goodman strengthens the board with extensive healthcare industry expertise, while the FDA submission represents a significant regulatory milestone for their therapeutic device development program.